3 results
Approved WMOCompleted
To identify the immunological response to combined SABR and pembrolizumab treatment in early stage NSCLC. Expression rates andactivation states of immune effector subsets will be assessed in tumor core biopsy specimens, peripheral blood and tumor…
Approved WMOCompleted
To evaluate the safety and initial feasibility of PEF treatment of NSCLC tumors prior to surgical resection.
Approved WMOCompleted
To evaluate the safety and clinical utility of PEF treatment of advanced stage or metastatic cancer following progression on immunotherapy